52 Week Range
As of on the XETRA ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Qiagen Reports Full Results For Second Quarter And First Half Of 2020
Qiagen Publishes Position Statement For Proposed Acquisition By Thermo Fisher
Davidson Kempner Says It Is Increasingly Apparent That Fair Value Of Qiagen Is Well In Excess Of Current Stock Price
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Biotechnology & Drugs
Independent Chairman of the Supervisory Board
Chief Executive Officer, Senior Vice President - Molecular Diagnostics Business Area, Member of the Executive Committee
Managing Director, Chief Financial Officer, Member of the Executive Committee
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Hedge fund Davidson Kempner said again on Thursday it will not be tendering its shares in Qiagen <QIA.DE>, days after Thermo Fisher Scientific <TMO.N> said its offer to buy the German genetic test maker expires soon.
Hedge fund Davidson Kempner said again on Thursday it will not be tendering its shares in Qiagen , days after Thermo Fisher Scientific said its offer to buy the German genetic test maker expires soon.
Hedge fund Davidson Kempner said on Monday it had raised its stake in takeover target Qiagen <QIA.DE> to 8% from 7.3% previously, reaffirming its opposition to Thermo Fisher's <TMO.N> 11.3 billion euro (10.1 billion pounds) bid.
Hedge fund Davidson Kempner has raised its stake in takeover target Qiagen <QIA.DE> to 7.3% from 5.1% previously, having rejected a sweetened offer for the German group from U.S. laboratory equipment supplier Thermo Fisher <TMO.N>.
Switzerland-based PSquared Asset Management on Wednesday unveiled a stake of more than 4% in Qiagen <QIA.DE>, adding it would not tender its shares into a $12.9 billion offer by U.S. laboratory equipment supplier Thermo Fisher <TMO.N>.
Corona Capital is a daily column updated throughout the day by Breakingviews columnists around the world with short, sharp pandemic-related insights.
The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.
Thermo Fisher Scientific raised its bid for Qiagen by 900 million euros ($1 billion) on Thursday but failed to win over a key investor who is seeking a higher price for the German genetic test maker.
Hedge fund Davidson Kempner said on Wednesday Thermo Fisher Scientific's <TMO.N> offer to buy German genetic test maker Qiagen <QIA.DE> was "wholly inadequate" and that it would not be tendering its shares into the deal at the current price.
Hedge fund Davidson Kempner said on Wednesday Thermo Fisher's acquisition offer for German genetic test maker Qiagen was "wholly inadequate" and that it would not tenderings its share into the deal at the current offer.
* DAVIDSON KEMPNER EUROPEAN PARTNERS SENDS LETTER TO QIAGEN NV
Davidson Kempner Capital Management LP said on Friday it considered Thermo Fisher Scientific's <TMO.N> current offer to acquire German genetic test maker Qiagen NV <QIA.DE> to be "inadequate" and would not tender its shares into the offer.
Davidson Kempner Capital Management LP said on Friday it considered Thermo Fisher Scientific's current offer to acquire German genetic test maker Qiagen NV to be "inadequate" and will not tender its shares into the offer.
U.S. 10-year Treasury yields are at their lowest since mid-May, the safe-haven yen is at a two-week high, Asian shares and U.S. stock futures are down sharply. European stocks have just opened down.
European shares extended losses for a fourth straight session on Friday on worries that an economic recovery may fizzle out as coronavirus cases continue to rise globally.
The German genetic testing firm Qiagen <QIA.DE> on Thursday reported a preliminary 18-19% rise in sales and a 68% rise in earnings per share in the second quarter amid strong demand for products used in coronavirus testing.
* Q2 NET SALES ROSE APPROXIMATELY 18-19% AT CONSTANT EXCHANGE RATES (CER) FROM $381.6 MILLION IN SAME PERIOD OF 2019
The coronavirus pandemic has boosted Qiagen's <QIA.DE> prospects and a takeover by Thermo Fisher no longer makes sense unless the offer is increased substantially, one of the German genetic test maker's top ten shareholders told Reuters on Friday.
The coronavirus pandemic has boosted Qiagen's prospects as a standalone company and a takeover by Thermo Fisher no longer makes sense unless the offer is increased substantially, one of the German genetic test maker's top ten shareholders told Reuters on Friday.
The following are some of the factors that may move German stocks on Wednesday:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.